Plasmodium falciparum phosphodiesterase 1 (PfPDE1) (PfPDE1)

Plasmodium falciparum phosphodiesterase 1 (PfPDE1) is a cyclic nucleotide phosphodiesterase enzyme involved in the regulation of intracellular signaling in the malaria parasite (UniProt: Q8I0V0) [1]. It functions by hydrolyzing the secondary messengers cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which are key regulators of various stages of the parasite's life cycle, including asexual development and the differentiation into sexual gametocytes (PlasmoDB: PF3D7_1209500) [2]. PfPDE1 is a dual-specificity enzyme, meaning it can degrade both cAMP and cGMP, thereby modulating the intracellular concentrations of these molecules required for signal transduction pathways that influence parasite motility and invasion (PubMed: 18614015) [3]. Because the cyclic nucleotide signaling machinery in Plasmodium is distinct from that in humans, PfPDE1 is considered a potential therapeutic target for the development of novel antimalarial agents, particularly those aimed at blocking transmission (PubMed: 23408914) [4]. Inhibition of PfPDE1 leads to an abnormal accumulation of cyclic nucleotides, which can disrupt essential biological processes and potentially prevent the parasite from completing its life cycle (PubMed: 28811340) [5]. However, a significant challenge in targeting PfPDE1 is achieving high selectivity to avoid inhibiting human phosphodiesterases, which could lead to adverse side effects such as visual disturbances or cardiovascular issues (PubMed: 25611365) [6].

Other names

PDE1PfPDEalphaPF3D7_1209500PFL0475wPhosphodiesterase 1

Inhibition of phosphodiesterase activity, leading to elevated intracellular cAMP and cGMP levels, which disrupts parasite signaling and development.